Diphencyprone (DCP) is a contact sensitiser used to treat dermatological conditions resulting from an altered immunological state, such as extensive alopecia areata. Adverse effects include local eczema with blistering, regional lymphadenopathy and contact urticaria. Rare adverse effects include an erythema multiforme-like reaction, hyperpigmentation, hypopigmentation and vitiligo. We report 4 patients with alopecia areata who developed the rare side-effect of vitiligo following DCP immunotherapy (Table 1).
This article is available only as a PDF. Please click on “Download PDF” to view the full article.